French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry

Summary Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted a real‐world registry‐based multice...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of haematology 2024-09, Vol.205 (3), p.990-998
Main Authors:	Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., Brisou, G., Talbot, A., Decaux, O., Houot, R., Le Gouill, S., Bigot, N., Facon, T., Corre, J., Moreau, P., Arnulf, B.
Format:	Article
Language:	English
Subjects:	Adult Aged Aged, 80 and over Antigens Apheresis B-Cell Maturation Antigen - immunology Bispecific antibodies Cell therapy cellular therapies Chimeric antigen receptors Early experience Feasibility studies Female France Humans immunotherapy Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Life Sciences Male Middle Aged Multiple myeloma Multiple Myeloma - therapy Neurotoxicity real‐world experience Receptors, Chimeric Antigen - therapeutic use Registries
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!